Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

Higher variability in systolic blood pressure increases long-term mortality risk in coronary artery disease patients.